title: Bioavailability of two clodronate formulations.
abstract: Sodium clodronate is effective in the management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastasis. Clinical and biochemical data underpin a licensed total daily dose of 1600-3200 mg.
authors.affiliation: Boehringer Ingelheim Limited, Bracknell, Berkshire.
authors.forename: G
authors.initials: G
authors.lastname: Lapham
authors.forename: K
authors.initials: K
authors.lastname: Aranko
authors.forename: H
authors.initials: H
authors.lastname: Hanhijärvi
authors.forename: D M
authors.initials: DM
authors.lastname: Humphreys
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000493:pharmacokinetics* / Q000600:supply & distribution*; D001682:Biological Availability; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D004002:Clodronic Acid / Q000494:pharmacology* / Q000600:supply & distribution*; D018592:Cross-Over Studies; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013607:Tablets; D013810:Therapeutic Equivalency
chemical_list: D018712:Analgesics, Non-Narcotic; D002214:Capsules; D013607:Tablets; D004002:Clodronic Acid